SavedAdd your journal

Journals / Interdisciplinary Medical Journal / 2021 / Cilt: 12 - Sayı: 44

The Role of Biochemical Markers Associated with Osteoporosis in Patients with Sickle Cell Anemia in Diagnosis

Orak Hücre Anemili Hastalarda Osteoporoz ile İlişkili Biyokimyasal Markerlerin Tanıdaki Yeri

Meryem KORKMAZ
Berna KUŞ
Emre DİRİCAN
Abdullah ARPACI
Pages
231–235
Publication Date
2021-12-24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion:It is predicted that the evaluation of bone turnover markers will contribute more to the diagnosis in understanding the effect of SCA on bone metabolism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The risk of osteopenia and osteoporosis has not been clearly defined in sickle cell anemia (SCA).
📊
Key Findings & Data:Methods: Our study included 33 patients with sickle cell anemia and 34 healthy controls.
💡
Conclusion & Impact:Conclusion:It is predicted that the evaluation of bone turnover markers will contribute more to the diagnosis in understanding the effect of SCA on bone metabolism.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Orak Hücre · Osteopeni · Osteoporoz

Abstract

Objective: The risk of osteopenia and osteoporosis has not been clearly defined in sickle cell anemia (SCA). In this study, it was aimed to evaluate the bone formation/resorption markers together and examine the relationships between each other in order to investigate the relationship between SCA and osteoporosis. Methods: Our study included 33 patients with sickle cell anemia and 34 healthy controls. Bone formation markers are Type 1 collagen N-terminal propeptide (P1NP), Type 1 collagen C-terminal propeptide (P1CP), Bone Alkaline Phosphatase (BALP) and Osteocalcin (OC), and bone resorption markers are Type 1 collagen carboxyterminal telopeptide (CTX), Pyridinoline (PYD) and Deoxypyridinoline (DPD) and Hydroxyproline (HYP) were analyzed. In addition, 25(OH)D levels of the groups were assayed. Results: The OC level was significantly higher in the patient group compared to the control group (p=0.016). 25(OH)D level was significantly decreased in the patient group compared to the control group (p=0.01). There was no statistically significant difference between the groups for both bone formation and resorption markers (PINP, PICP, PYD, DPD, BALP, CTX, HYP). Conclusion:It is predicted that the evaluation of bone turnover markers will contribute more to the diagnosis in understanding the effect of SCA on bone metabolism.

Özet

Amaç: Orak hücreli anemi (OHA)’de osteopeni ve osteoporoz riski net olarak ortaya konmamıştır. Bu çalışmada OHA-osteoporoz ilişkisini araştırmak amacıyla kemik yapım/yıkım belirteçleri bir arada değerlendirilerek aralarındaki korelasyonun incelenmesi amaçlandı. Gereç ve Yöntem: Çalışmanın hasta grubu 33 orak hücreli birey ve kontrol grubu ise 34 sağlıklı bireyden oluşturuldu. Kemik yapım belirteçlerinden Tip 1 kollajen N-terminal propeptit (P1NP), Tip 1 kollajen C-terminal propeptit (P1CP), Kemik Alkalen Fosfataz (BALP) ve Osteokalsin (OC), kemik yıkım belirteçlerinden ise, Tip 1 kollajen karboksiterminal bağlı telopeptit (CTX), Pridinolin (PYD) ve Deoksipridinolin (DPD) ve Hidroksiprolin (HYP) analiz edildi. Ayrıca grupların 25(OH)D düzeyleri ölçüldü. Bulgular: OC düzeyi hasta grubunda kontrol grubuna kıyasla anlamlı derecede yüksekti. (p=0.016). 25(OH)D düzeyi hasta grubunda kontrol grubuna kıyasla önemli ölçüde düşüktü. (p=0.01). Gruplar arasında diğer yapım ve yıkım belirteçlerinde (PINP, PICP, PYD, DPD, BALP, CTX, HYP) istatistiksel olarak anlamlı fark bulunmadı. Sonuç: OHA’nın kemik metabolizmasına etkisinin anlaşılmasında kemik döngüsü belirteçlerinin de değerlendirilmesinin tanıya daha fazla katkıda bulunacağı öngörülmüştür.

🔖

Cite This Article

KORKMAZ, M., KUŞ, B., DİRİCAN, E., ARPACI, A. (2021). The Role of Biochemical Markers Associated with Osteoporosis in Patients with Sickle Cell Anemia in Diagnosis. Interdisciplinary Medical Journal, Cilt: 12 - Sayı: 44, 231–235. https://ajindex.com/articles/887561

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Mandal AK, Mitra A, Das R. Sickle Cell Hemoglobin. Subcell Biochem. 2020;94:297-322. DOI:https://doi.org/ 10.1007/978-3-030-41769-7_12 Pinto VM, Balocco M, Quintino S, Forni GL. Sickle cell disease: a review for the internist. Intern Emerg Med. 2019;14(7):1051-64. https://doi.org/ 10.1007/s11739-019-02160-x Aguilar C, Vichinsky E, Neumayr L. Bone and joint disease in sickle cell disease. Hematol Oncol Clin North Am. 2005;19(5):929-41, viii. https://doi.org/ 10.1016/j.hoc.2005.07.001 Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-31. https://doi.org/ 10.1016/S0140-6736(10)61029-X Kim HK, Kim MG, Leem KH. Osteogenic activity of collagen peptide via ERK/MAPK pathway mediated boosting of collagen synthesis and its therapeutic efficacy in osteoporotic bone by back-scattered electron imaging and microarchitecture analysis. Molecules. 2013;18(12):15474-89.
  2. Guillerminet F, Beaupied H, Fabien-Soulé V, Tomé D, Benhamou CL, Roux C, et al. Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. Bone. 2010;46(3):827-34. https://doi.org/ 10.1016/j.bone.2009.10.035 da Silva Junior GB, Daher EeF, da Rocha FA. Osteoarticular involvement in sickle cell disease. Rev Bras Hematol Hemoter. 2012;34(2):156-64. https://doi.org/ 10.5581/1516-8484.20120036 Nolan VG, Nottage KA, Cole EW, Hankins JS, Gurney JG. Prevalence of vitamin D deficiency in sickle cell disease: a systematic review. PLoS One. 2015;10(3):e0119908. https://doi.org/10.1371/journal.pone.0119908
  3. Garrido C, Cela E, Beléndez C, Mata C, Huerta J. Status of vitamin D in children with sickle cell disease living in Madrid, Spain. Eur J Pediatr. 2012;171(12):1793-8. https://doi.org/ 10.1007/s00431-012-1817-2
  4. Nelson DA, Rizvi S, Bhattacharyya T, Ortega J, Lachant N, Swerdlow P. Trabecular and integral bone density in adults with sickle cell disease. J Clin Densitom. 2003;6(2):125-9. https://doi.org/ 10.1385/jcd:6:2:125 Miller RG, Segal JB, Ashar BH, Leung S, Ahmed S, Siddique S, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006;81(4):236-41. https://doi.org/ 10.1002/ajh.20541 Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer. 2006;47(7):901-6. https://doi.org/ 10.1002/pbc.20681 Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et a